Noriko Shimasaki Selected Research

Noriko Shimasaki Research Topics

14	Neoplasms (Cancer) 09/2022 - 02/2004
4	Leukemia 01/2020 - 05/2009
3	Lymphoma (Lymphomas) 01/2020 - 02/2006
3	Infections 01/2018 - 01/2016
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2009 - 02/2006
2	Hepatocellular Carcinoma (Hepatoma) 01/2016 - 08/2013
1	Exanthema (Rash) 09/2022
1	Nasopharyngeal Carcinoma 09/2022
1	Hepatitis B 02/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2017
1	Communicable Diseases (Infectious Diseases) 09/2016
1	Melanoma (Melanoma, Malignant) 01/2016
1	Cross Infection (Nosocomial Infection) 01/2016
1	Experimental Arthritis 04/2011
1	Arthritis (Polyarthritis) 04/2011
1	Inflammation (Inflammations) 04/2011
1	Rheumatoid Arthritis 04/2011
1	Osteosarcoma (Osteogenic Sarcoma) 08/2010
1	Ewing Sarcoma (Sarcoma, Ewing) 08/2010
1	Rhabdomyosarcoma 08/2010
1	Neuroblastoma 08/2010
1	Mucositis 02/2006
1	Vomiting 02/2006
1	Genomic Instability 10/2004
1	Chromosome Aberrations (Chromosome Abnormalities) 10/2004
1	Intussusception 05/2004
1	Pneumatosis Cystoides Intestinalis 05/2004
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 02/2004

6	Chimeric Antigen ReceptorsIBA 01/2022 - 08/2012
4	Methotrexate (Mexate)FDA LinkGeneric 04/2011 - 02/2006
2	AerosolsIBA 01/2018 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 08/2013
2	AntigensIBA 01/2016 - 01/2013
2	LigandsIBA 08/2010 - 05/2009
2	Reduced Folate Carrier ProteinIBA 05/2008 - 02/2006
2	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 05/2008 - 02/2006
1	Cetuximab (Erbitux)FDA Link 09/2022
1	ErbB Receptors (EGF Receptor)IBA 09/2022
1	niranthinIBA 02/2022
1	LignansIBA 02/2022
1	CyclopropanesIBA 02/2022
1	Bevacizumab (Avastin)FDA Link 01/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	Hazardous Substances (Hazardous Materials)IBA 01/2018
1	Interleukin-15 (Interleukin 15)IBA 05/2017
1	4-1BB Ligand (4 1BB Ligand)IBA 05/2017
1	AntibodiesIBA 09/2016
1	Peptides (Polypeptides)IBA 01/2016
1	Indicators and Reagents (Reagents)IBA 01/2016
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2016
1	Messenger RNA (mRNA)IBA 04/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2011
1	Pharmaceutical PreparationsIBA 04/2011
1	InterleukinsIBA 05/2009
1	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 05/2008
1	MutagensIBA 10/2004
1	Rituximab (Mabthera)FDA Link 02/2004

7	Therapeutics 09/2022 - 05/2009
5	Immunotherapy 01/2020 - 05/2009
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2016 - 05/2009
2	Protective Clothing 01/2018 - 01/2016
2	Cord Blood Stem Cell Transplantation 05/2004 - 02/2004
1	Drug Therapy (Chemotherapy) 11/2017
1	Blood Component Removal (Apheresis) 11/2016
1	Chronotherapy 04/2011
1	Maintenance Chemotherapy 05/2008